Skip to main content

Table 1 Baseline characteristics of the sample

From: Sexuality and cancer in adolescents and young adults - a comparison between reproductive cancer patients and patients with non-reproductive cancer

  Total (N = 577) Women n = 424 (73.5%) Men n = 153 (26.5%)
All NRC n = 223 RC n = 201 df p All NRC n = 103 RC n = 50 df p
Age at diagnosis - Mean (SD) 29.30 (6.09) 29.09 (6.00) 27.72 (5.99) 32.32 (5.02) 422 ≤.001*** 27.76 (6.09) 27.26 (6.24) 28.78 (5.68) 151 .143
Months since diagnosis - Mean (SD) 11.89 (7.99) 11.78 (7.60) 11.85 (8.48) 11.69 (6.51) 406 .829 12.22 (9.01) 13.17 (8.97) 10.26 (8.87) 145 .061
  N (%) n (%) n (%) n (%)    n (%) n (%) n (%)   
Partnershipa 391 (67.8) 308 (73.2) 154 (69.1) 154 (77.8) 1 .044* 83 (54.2) 54 (52.4) 29 (58.0) 1 .516
Children 184 (31.9) 152 (35.8) 68 (30.5) 84 (41.8) 1 .015* 32 (21.1) 24 (23.5) 8 (16.0) 1 .285
Highest educational degreeb      5 .509     5  
 No educational degree 6 (1.0) 3 (0.7) 3 (1.3) 0    3 (2.0) 3 (3.0) 0   
 Basic educational degree (< 10 years) 37 (6.5) 23 (5.5) 13 (5.8) 10 (5.2)    14 (9.2) 9 (8.8) 5 (10.0)   
 Secondary educational degree (10 years) 90 (33.2) 128 (32.8) 74 (33.2) 64 (32.2)    52 (34.2) 34 (33.3) 18 (36.0)   
 High school degree (> 10 years) 340 (59.3) 257 (61.1) 133 (59.6) 124 (62.6)    83 (54.5) 56 (54.9) 27 (54.0)   n/a
Housing/living conditionsc      3 ≤.001***     3 .200
 Single 131 (22.7) 95 (23.6) 49 (23.0) 46 (12.2)    36 (24) 20 (19.8) 16 (32.7)   
 Living with partner 298 (51.6) 238 (59.1) 110 (51.6) 128 (67.4)    60 (40) 41 (40.6) 19 (38.8)   
 Living in parental household 92 (16.6) 51 (12.7) 40 (18.8) 11 (5.8)    41 (27.3) 32 (31.7) 9 (18.4)   
 Shared community 32 (5.8) 19 (4.7) 14 (6.6) 5 (2.6)    13 (8.7) 8 (7.9) 5 (10.2)   0
Reproductive Cancer [C50-C57, C62] 251 (43.5) 201 (47.4)     n/a 50 (32.7)     
Non-Reproductive Cancer [All other C] 326 (56.5) 223 (52.6)     103 (67.3)     n/a
Cancer diagnosis       n/a      n/a
 [C50] Breast 150 (26.0) 150 (35.4)     0    
 [C81] Hodgkin’s Lymphoma 99 (17.2) 66 (15.6)     33 (21.7)    
 [C51-C57] Gynecological 51 (8.8) 51 (12.0)     0    
 [C62] Testicular 50 (8.7) 0     50 (32.7)    
 [C82-C90] Non-Hodgkin’s Lymphoma 42 (7.3) 22 (5.2)     20 (13.2)    
 Others 41 (7.1) 24 (5.7)     17 (11.1)    
 [C91-C95] Haematological 38 (6.6) 20 (4.7)     16 (10.5)    
 [C73] Thyroid 32 (5.5) 30 (7.1)     2 (1.3)    
 [C15-C26] Gastrointestinal 29 (5.0) 21 (5.0)     8 (5.2)    
 [C40-C41, C46-C49] Sarcoma 26 (4.5) 20 (4.7)     6 (3.9)    
 [C43] Melanoma 19 (3.3) 18 (4.2)     1 (0.7)    
Therapies (multiple answers possible)d
 Chemotherapye 443 (76.8) 310 (73.1) 152 (68.2) 158 (78.6) 2 .015* 133 (86.9) 91 (88.5) 42 (84) 2 .454
 Surgery 427 (74.0) 325 (76.6) 139 (62.3) 186 (92.5) 2 ≤.001*** 102 (66.7) 54 (52.4) 48 (96) 2 ≤.001***
 Radio and nuclear therapye 264 (45.8) 207 (48.8) 92 (41.3) 115 (57.2) 2 ≤.001*** 57 (37.3) 56 (54.4) 1 (2) 2 ≤.001***
 Stem Cell/bone marrow transplantation 33 (5.7) 23 (5.5) 21 (9.4) 2 (1.0) 2 ≤.001*** 10 (6.6) 9 (8.7) 1 (2) 2 .114
  1. Males and females are listed separately and further broken down into groups of RCs and NRCs. t-tests and χ2 tests were performed between NRCs and RCs for each gender
  2. Missing: a3 (0.5%); b4 (0.7%); c24 (4.2%); dDue to further validation there are deviations to the baseline medical therapies published in the study protocol [44]; eincluding Radio-Chemotherpy; n/a not applicable
\